Immuvera Therapeutics is pleased to announce the appointment of Professor David J. Argyle to the company’s International Medical Advisory Board.

Professor Argyle is one of the most respected leaders in veterinary oncology and comparative cancer research. He currently serves as Vice Principal and Head of the College of Medicine and Veterinary Medicine at the University of Edinburgh and previously served as Head of School and Dean for Veterinary Medicine. Over the course of his career, he has built an internationally recognised profile spanning clinical veterinary oncology, translational cancer research, education, and industry collaboration.

He is a Recognised Specialist in Oncology, a Foundation Diplomate of ECVIM-CA (Oncology), and has held major leadership roles across the veterinary profession, including as President of the European Society of Veterinary Oncology. His experience also includes advisory and consulting work with leading animal health companies, as well as expert contribution to the approval of new veterinary oncology products in Europe.

Professor Argyle brings deep expertise in canine cancer biology, metastasis, immunology, translational oncology, and the development of novel therapeutics, making his perspective highly relevant to Immuvera’s development of Nebumet, the company’s inhaled immunotherapy platform designed to prevent and treat lung metastases in dogs.

His appointment strengthens Immuvera’s scientific and clinical foundation as the company advances Nebumet toward pivotal development and regulatory progression.

Lars Moe, CMO of Immuvera Therapeutics, said:
“Professor Argyle is a highly respected leader in veterinary oncology and comparative cancer research. His scientific depth, clinical insight, and understanding of translational development will be highly valuable to Immuvera as we continue advancing Nebumet.”

Professor Argyle’s appointment reflects Immuvera’s commitment to building a world-class advisory network around the development of new therapies for metastatic cancer in dogs.